

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS**

JOHN HANCOCK LIFE INSURANCE
COMPANY, JOHN HANCOCK VARIABLE
LIFE INSURANCE COMPANY, and
MANULIFE INSURANCE COMPANY (f/k/a
INVESTORS PARTNER INSURANCE
COMPANY),

Plaintiffs,

v.

ABBOTT LABORATORIES,

Defendants.

CIVIL ACTION NO. 05-11150-DPW
Hon. Judge Douglas P. Woodlock

**ABBOTT LABORATORIES' REVISED OBJECTIONS TO HANCOCK'S TRIAL
EXHIBITS**

Defendant Abbott Laboratories ("Abbott") respectfully submits its revised objections to Hancock's trial exhibits. Abbott has substantially narrowed its objections to Hancock's Trial Exhibits. Abbott reserves any and all rights to supplement these objections during trial. Attached as Exhibit A is a key to Abbott's objections to Hancock's exhibits. Attached as Exhibit B is Hancock's Trial Exhibit List with Abbott's revised objections.

Respectfully submitted,

Dated: February 29, 2008

ABBOTT LABORATORIES

By its attorneys

/s/ Eric J. Lorenzini

Eric J. Lorenzini

Michael S. D'Orsi
Peter E. Gelhaar (BBO #188310)
Michael S. D'Orsi (BBO #566960)
DONNELLY, CONROY & GELHAAR LLP
1 Beacon St., 33rd Floor
Boston, Massachusetts 02108
(617) 720-2880

and

Jeffrey I. Weinberger (Admitted Pro Hac Vice)
Gregory D. Phillips (Admitted Pro Hac Vice)
Eric J. Lorenzini (Admitted Pro Hac Vice)
Ozge Guzelsu (Admitted Pro Hac Vice)
MUNGER, TOLLES & OLSON LLP
355 South Grand Avenue, 35th Floor
Los Angeles, CA 90071
(213) 683-9100

Counsel for Abbott Laboratories

CERTIFICATE OF SERVICE

I hereby certify that this document(s) filed through the ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non registered participants on February 29, 2008.

Date: February 29, 2008.

/s/ Eric J. Lorenzini

EXHIBIT A

Exhibit A**John Hancock Life Insurance Company, et al. v. Abbott Laboratories****Abbott's Objections to Hancock's Revised List of
Trial Exhibits, as Amended Through February 28, 2008****Key**

Code	Objection
Lack of Authentication/Foundation	Lack of Authentication or Lack of Foundation -- Federal Rule of Evidence 901.
Hearsay	Hearsay or Double-Hearsay -- Federal Rules of Evidence 802 and 805.
Improper Opinion	Impermissible Lay or Expert Opinion -- Federal Rules of Evidence 701 and 702.
Irrelevant	Irrelevant -- Federal Rule of Evidence 401.
Incomplete or Poor Copy	Incomplete Document or Poor Copy -- Hancock did not designate the complete document or did not designate a legible copy, therefore, admission of the exhibit could be misleading and unfair. Federal Rules of Evidence 1002 and 1003
No Objection	No Objection.
Multiple Documents	The Bates range provided by Hancock contains more than one document, therefore introduction as a single exhibit could be misleading and unfair. Abbott reserves any and all objections to these documents and requests that Hancock identify these documents with separate exhibit numbers.
Settlement	The document is inadmissible under Federal Rule of Evidence 408.

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
A	12/9/1999	MMPI Working Group Meeting Minutes	ABBT0053710-11	No Objection
B	3/9/2000	Matrix Metalloproteinase Inhibitors Project - Discovery Development Candidate Meeting	ABBT0141929-83	No Objection
C	7/14/2000	2001 Plan Assumption Memo	ABBT0037399-463	No Objection
D	Aug-00	July 2000 Top Issues	ABBT0017616-19	Hearsay
E	8/1/2000	ABT-518 Transition Strategy (MMPI), August 2000	ABBT256634-45	No Objection
F	11/00/2000	Information for Clinical Investigators, ABT-518	ABBT0055691-772	No Objection
G	11/8/2000	Oncology Portfolio Analysis Inputs - Project List, Product Profiles and Probabilities of Technical Success - Draft for Team Review, November 8, 2000	ABBT292350, ABBT292365, ABBT302701, ABBT302721	Incomplete Document
H	1/11/2001	MMPI Working Group Meeting, Meeting Objective: ABT-518 Program Update	ABBT0045274-276	No Objection
I	2/1/2001	ABT-518 Monthly Report, February 2001	ABBT0000343-48	Hearsay
J	2/1/2001	ABT-518 Descriptive Memorandum, February 2001	ABBT0004032-39	No Objection
K	2/4/2001	Oncology Status Report	ABBT0045333-35	No Objection
L	3/1/2001	ABT-518 Monthly Report, March 2001	ABBT0000349-54	Hearsay
M	3/7/2001	Abbott Portfolio Review, March 7-9, 2001	ABBT0013224-32	No Objection
N	3/8/2001	MMPI Monthly Meeting Agenda	ABBT0045253	No Objection
O	3/8/2001	MMPI Working Group Meeting Minutes	ABBT300143-44	No Objection
P	3/9/2001	Oncology Status Report	ABBT0045324-326	Hearsay
Q	3/9/2001	Letter from Tom Capetan to Dr. Nisen re: Report on ABT 518-Evaluation in Ocular Angiogenic Models	ABBT0049922-26	Hearsay Irrelevant
R	3/12/2001	Email from Philip M. Deemer to sblewitt@jhancock.com@internet re MMPI Program Update	ABBT0004031-39	No Objection
S	3/12/2001	Email from Diane L. D'Amico to jhm@nki.nl re M00-235 Update	ABBT0033104	No Objection
T	3/12/2001	Email from Diane L. D'Amico to jhm@nki.nl re M00-235 Update	ABBT0055172-73	No Objection
U	3/13/2001	Email from Jim Looman to Azmi A. Nabulsi et al. re NKI Study	ABBT0033093	No Objection
V	3/13/2001	Email from Paige Gjelsten to Jim Looman et al. re M00-235 Study Hold Lifted	ABBT0033094	No Objection
W	3/14/2001	Email from Diane L. D'Amico to l.v.beerepoot@azu.nl re M00-235: Validated PD Methods	ABBT0046350	No Objection
X	3/14/2001	Email from Diane L. D'Amico to Azmi A. Nabulsi re Erroneous Dosing of Patient	ABBT0056817	No Objection
Y	3/16/2001	Email from Philip M. Deemer to Joyce L. Devault re For Overhead	ABBT0004507-09	No Objection
Z	3/19/2001	Email from Jim Looman to Diane L. D'Amico re M00-235 Update	ABBT0055205-06	No Objection
AA	3/19/2001	Email from Diane L. D'Amico to Willy Jansen et al. re M00-235 Update	ABBT0033096-97	No Objection
AB	3/20/2001	E-mail from Deemer to Nisen	ABBT245847	No Objection
AC	3/21/2001	Email from Jim Looman to Diane L. D'Amico re Restart 518 Study	ABBT0508262	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
AD	3/21/2001	Email from Perry D. Nisen to Philip M. Deemer re Hancock and Alcon	ABBT246501	No Objection
AE	3/22/2001	Email from Paige Gjelsten to MMPI Team re MMPI Working Group Meeting Minutes: 3/8/01	ABBT300130-32, ABBT300142-44	No Objection
AF	3/22/2001	Email from Philip M. Deemer to Perry D. Nisen re Hancock and Alcon	AL000403	No Objection
AG	4/16/2001	E-mail from Perry D. Nisen to Azmi A. Nabulsi re: DMC Project Review Meetings	ABBT0063627-28	No Objection
AH	5/1/2001	Monthly Highlights - Key Project Progress	ABBT0000361-65	Hearsay
AI	5/1/2001	ABT-518 Monthly Report, May 2001	ABBT143915.UR-20	Hearsay
AJ	5/2/2001	Email from Tamara L. Garavalia to Michaela L. James et al. re: ABT518	ABBT0055426	No Objection
AK	5/11/2001	Oncology Status Report	ABBT0045302-304	No Objection
AL	5/20/2001	Email from Perry D. Nisen to Azmi A. Nabulsi re: MMPI	ABBT0064234	No Objection
AM	5/22/2001	E-mail from Nisen to Leonard with ASCO slides	ABBT0063642-49	No Objection
AN	5/22/2001	Email from Perry D. Nisen to John M. Leonard re: ABT-518	ABBT0064226	Incomplete
AO	5/25/2001	Email from Diane L. D'Amico to Diane C. Bronson et al. re: ABT-518 Tox	ABBT0059368	No Objection
AP	5/25/2001	Email from Diane L. D'Amico to Lise I. Loberg re: ABT-518 Tox	ABBT0061200	No Objection
AQ	5/28/2001	Email from Diane C. Bronson to Diane L. D'Amico re: ABT-518 Tox	ABBT0057052	No Objection
AR	5/28/2001	Email from Diane C. Bronson to Lise I. Loberg re: ABT-518 Tox	ABBT0155970	No Objection
AS	5/29/2001	Email from Lise I. Loberg to William M. Bracken et al. re: resume ABT-518 activities: FALSE ALARM!	ABBT0157559	No Objection
AT	6/4/2001	Oncology Status Report	ABBT0045296-97	No Objection
AU	6/4/2001	Email from 8776893456@skytel.com to Diane L. D'Amico re: MMPI	ABBT0057906	No Objection
AV	6/4/2001	Email from Thomas J. Lyons to Kenneth D. Stiles re: MMPI-Phase I Study Options	ABBT334695-97	No Objection
AW	6/6/2001	Email from Lise I. Loberg to William M. Bracken et al. re: ABT-518 update	ABBT0157798-99	No Objection
AX	6/7/2001	MMPI Working Group Meeting Minutes	ABBT0026340-42	No Objection
AY	6/7/2001	MMPI Monthly Meeting Agenda	ABBT0045226-27	No Objection
AZ	6/7/2001	MMPI Working Group Meeting Minutes	ABBT0057877-878	No Objection
BA	6/14/2001	Email from Diane C. Bronson to Paige Gjelsten re: MMPI Meeting Minutes from 6/7/01	ABBT0033472-74	No Objection
BB	6/21/2001	M00-235 Teleconference: Schellens Notification of Study Termination	ABBT0033089-98, 101, 104-108, 110, 113-114, 117-119	Multiple Documents Hearsay
BC	7/30/2001	Email from Philip Deemer to Dan Norbeck re MMPI	ABBT245647	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
BD	8/10/2001	Letter to Perry Nisen from Steven K. Davidsen, Ph.D. re: ABT-518	ABBT0049970-77	No Objection
BE	8/14/2001	Memo from Perry Nisen to Dan Norbeck et al. re: ABT-518	ABBT0049980-81	No Objection
BF	10/11/2001	Email from Phillip M. Deemer to Bruceb@amgen.com@internet re: Licensing Opportunities	ABBT245651	No Objection
BG	5/17/2002	Clinical Study Report R&D/02/118 - A Phase I Escalating Multiple Dose Study Of Matrix Metalloproteinase Inhibited (ABT-518) In Patients With Advanced Cancer; ABT-518/ Protocol M00-235	ABBT0033583-658	No Objection
BH	9/15/2005	Email from Jane A. Hoff-Smith to Suzanne Lebold et al. regarding Update on ABT-518	ABBT372504	No Objection
BI	00/00/00	ABT-518/Total Base	ABBT0003362-64, 3368-70	Hearsay
BJ	00/00/00	Proposed Program Rationalization	ABBT0018775	Lack of Authentication, Hearsay Incomplete
BK	00/00/00	Letter from Azmi to Jim re project review with upper management on Wednesday	ABBT0507866	No Objection
BL	00/00/00	Timeline of events occurring with Study M00-235 in the Netherlands	ABBT0518377-378	Hearsay
BM	00/00/00	Abbott Laboratories Project Overview - ABT 518- CLOSED	ABBT372493-94	No Objection
BN	3/9/2000	MMPI A-291518 Discovery Development Candidate Approval Slide	ABBT0141509	Incomplete
BO	3/21/2001	Email from Perry Nisen to Philip Deemer re Hancock and Alcon	ABBT0004019	No Objection
BP	3/9/2000	Email from Aldona T. Matalonis to hg@clinphone.com@internet re Suspend Work on Abbott M99-115 IVR Project	ABBT0150827	Irrelevant
BQ	9/1/1998	A-173259.47: A Novel Potent, Non-Opioid Analgesic	ABBT0023920-81	Authentication / Hearsay (handwritten notes)
BR	1/15/1999	Memo to Leonard re Meeting Minutes for Analgesia Venture Portfolio Review	ABBT0005027-37	No Objection
BS	2/24/1999	Email from Kacos to Boyd re Analgesia Portfolio Review, with slides	ABBT0114450-519	No Objection
BT	3/12/1999	Letter from McCarthy to Meyer enclosing documents for ABT-594 European Advisory Meeting	ABBT0024357, 24363-69	No Objection
BU	4/1/1999	ABT-259 Transition Strategy dated April 1999	ABBT0020594-611	Incomplete
BV	6/1/1999	ABT-594 Development Plan dated June, 1999	ABBT0018986-0019095	No Objection
BW	10/30/1999	Email from Gary D Jones to Tamara L Garavalia re meeting	ABBT0144769-71	No Objection
BX	11/17/1999	Email from Aldona T Matalonis to Catherine K Kacos re 3 page summary sheet for ALZA	ABBT0105015-19	No Objection
BY	12/21/1999	Email from James W Thomas to Fred W. Siebert et al.re 114 Sample Size	ABBT0051889	No Objection
BZ	1/24/2000	Email from Christopher J Silber to Grace C Dunn et al. re Analgesia Venture Monthly Highlights	ABBT0159624	No Objection
CA	1/31/2000	Abbott/NeuroSearch, Joint Research Council, January 31 - February 1, 2000	ABBT0022519-69	No Objection
CB	3/1/2000	March 2000, ABT-594 Project Status Report	ABBT0004401-09	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
CC	4/1/2000	ABT-594 Descriptive Memorandum	ABBT0107546-551	No Objection
CD	5/31/2000	Email from Marilyn J Collicott attaching site breakdown/enrollment for M99-114	ABBT0033462-67	No Objection
CE	6/1/2000	June 2000, ABT-594 Project Status Report	ABBT0004422	Incomplete
CF	6/9/2000	Email from Marilyn Collicott to Bruce McCarthy re Updates fro M99-114 Phase IIb Meeting	ABBT0166642-43	No Objection
CG	6/19/2000	Email from Kathy Starkey to Chris Speh re Project Update	CNSTLA 0087-88	Hearsay Improper Opinion
CH	7/6/2000	Email from Tamara L Garavalia to Aldona T Matalonis et al. re M99-114 300 mcg dose group	ABBT0161395	No Objection
CI	7/7/2000	Email from Steve Blewitt to Steve Cohen re Questions	ABBT0004016	Hearsay
CJ	7/7/2000	Email from Bruce McCarthy to David D Morris et al. re M99-114 Protocol Change Discussion	ABBT0082516	No Objection
CK	7/25/2000	Email from Michael Biarnesen to Aldona Matalonis re RQA Auditor Assignment for Analgesia Venture	ABBT0161644-45	No Objection
CL	8/1/2000	August 2000, ABT-594 Project Status Report	ABBT0004436	Incomplete
CM	8/1/2000	ABT-594 Product Development Team Meeting, Minutes	ABBT0042271-75	No Objection
CN	8/1/2000	ABT-594 Product Development Team Meeting, Minutes	ABBT0162183-86	No Objection
CO	8/21/2000	Email from Laura Robinson to Andrea Landsberg re RE: ABT-594 Commercial Section w/Laura Robinson Input	ABBT0161930-69	No Objection
CP	8/22/2000	Email from James W Thomas to Bruce McCarthy re 114 fax ae numbers	ABBT0502613	Hearsay
CQ	8/29/2000	Email from James Thomas to Catherine Kacos re M99-114 graph data	ABBT0080232-33	No Objection
CR	8/31/2000	Email from Marilyn J Collicott to Christopher J Silber re M99-114 Extension letter	ABBT0113703-04	No Objection
CS	8/31/2000	Letter from Marilyn Collicott re Protocol M99-114: A Randomized, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy of ABT-594 to Placebo in Subjects with Painful Diabetic Neuropathy	ABBT241302	No Objection
CT	9/1/2000	September 2000, ABT-594 Project Status Report	ABBT0004443-47	No Objection
CU	Sep-00	September Strategy Update	ABBT0577811-34	No Objection
CV	9/11/2000	Email from Christopher J Silber to Catherine K Kacos re Trip Report: Visit to Gibson, Biton, Kipnes, Hewitt	ABBT0109317-22	Hearsay
CW	9/26/2000	Randomized, Double-Blind, Placebo Controlled Evaluation of the Safety and Efficacy of ABT-594 in Subjects with Painful Diabetic Polyneuropthy; The 594/M99-114 Study, Centralized Patient Recruitment Program	ABBT240985-241001	Hearsay
CX	9/27/2000	Email from Andrea Landsberg to Christopher J Silber re Purdue CDA	ABBT0105034	No Objection
CY	9/28/2000	Email from James W Thomas to Rebecca L Brown re ABT-594 M99-114 Slides for David with attached notes	ABBT0051892-904	Authentication / Hearsay (handwritten notes)
CZ	9/28/2000	Clinical Trial Recruitment and Centralized Screening Program For Painful Diabetic Neuropathy	ABBT233741-49	Hearsay
DA	9/29/2000	Email from Christopher J Silber to John M Leonard re 594 Neuropathic pain study	ABBT0105598	No Objection
DB	10/1/2000	October 2000, ABT-594 Project Status Report	ABBT0004448-54	No Objection
DC	10/3/2000	Email from Andrea Landsberg to Robert J Weiland re ABT 594/963 Purdue meeting	ABBT0117782	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
DD	10/9/2000	Email from Marilyn J Collicott to Susan E Nunn et al. re M99-114	ABBT237155-59	No Objection
DE	10/12/2000	Email from Mike Williams to Jennifer Smoter re Re: NNR documents	ABBT0118072	No Objection
DF	10/24/2000	Email from Christopher J Silber to Nancy M Palbicke re Attached question list	ABBT0114445-47	No Objection
DG	10/27/2000	Email from Andrea Landsberg to Christopher J Silber et al. re 594 Leiden presentation	ABBT0116819-36	No Objection
DH	11/1/2000	November 2000 ABT-594 Project Status Report	ABBT0004455-59	No Objection
DI	11/1/2000	Email from Robert J Weiland to Christopher J Silber re Re: Pharmacia meeting	ABBT0107163	No Objection
DJ	Nov-00	November 2000 ABT-594 Status Report	ABBT0108785-790	No Objection
DK	11/1/2000	Email from Bruce McCarthy to Christopher J Silber re Re: Pharmacia meeting	ABBT010893-94	No Objection
DL	11/1/2000	ABT-594 Descriptive Memorandum dated November 2000	ABBT144600.UR-09	Hearsay
DM	11/2/2000	Email from James Sullivan to Robert J. Weiland re Re: Pharmacia meeting	ABBT0120836-37	No Objection
DN	11/9/2000	Email from Bruce McCarthy to Robert J Weiland et al. re ABT-594 Partnership Strategy Meeting	ABBT0102187-88	No Objection
DO	11/13/2000	Email from Linda Orovitz to Chris Speh, et al re Info for Abbott mtg	CNSTLA 0463-70	Hearsay
DP	11/17/2000	PowerPoint ABT-594 Project Review	ABBT0019102-37	No Objection
DQ	11/17/2000	Draft Project Review: ABT 594 Agenda	ABBT0125290-91	Incomplete
DR	11/22/2000	Email from Bruce McCarthy to David D Morris et al. re ABT-594 M99-114 Study Size Discussion	ABBT0109399-400	No Objection
DS	11/29/2000	Email from Michael K Biarnesen to Andrea Landsberg re Re: ABT 594 forecast scenarios for BD partnering	ABBT0119091-96	No Objection
DT	11/30/2000	Email from Elizabeth Kowaluk to Bryan F Cox re Re: 12/6 meeting	ABBT326427	No Objection
DU	12/1/2000	December 2000 ABT-594 Project Status Report	ABBT0004660-64	No Objection
DV	12/6/2000	Email from Marilyn J Collicott to Michael K Biarnesen re Re: November Monthly Project Status Report, ABT-594	ABBT242373 ABBT242394	No Objection
DW	12/13/2000	Chart and Notes re Abbott M99-114	CNSTLA 0530-31	Hearsay Irrelevant Improper Opinion
DX	12/14/2000	Email from Marilyn J Collicott to Marian L Borgstrom et al. re Study M99-114	ABBT236951-52	No Objection
DY	12/21/2000	Email from James W Thomas to Bruce McCarthy re Re: n/v rate	ABBT0079831-34	No Objection
DZ	12/21/2000	Email from James W Thomas to Bruce McCarthy re Re: n/v rate	ABBT0080180-84	No Objection
EA	12/21/2000	Email from Bruce McCarthy to Christopher J Silber re landsberg email	ABBT0106516	No Objection
EB	12/21/2000	Email from Jennifer Dart to Christopher J Silber et al. re Analgesia Internal Review Notes	ABBT0108041	No Objection
EC	12/21/2000	Email from Bruce McCarthy to Christopher J Silber re Purdue presentation	ABBT0118174-203	No Objection
ED	1/1/2001	January 2001 ABT-594 Project Status Report	ABBT0000322-27	No Objection
EE	1/15/2001	Email from Bruce McCarthy to Christopher J Silber et al. re AEs for preterms - blinded look	ABBT0108884-85	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
EF	1/23/2001	ABT-594 Titration Optimization Initial Brainstorm Discussion, Agenda, January 23, 2001	ABBT0504097	Authentication / Hearsay (handwritten notes)
EG	1/25/2001	Email from Jennifer Dart to Prioritization Meeting Attendees re APU Priorization Meeting	ABBT0012433 ABBT0012454	Incomplete
EH	1/25/2001	Email from Christopher J Silber to James Sullivan re ABT-594	ABBT0102282-344	No Objection
EI	2/1/2001	ABT-594 Monthly Report, February 2001	ABBT0000412-417	No Objection
EJ	2/1/2001	Email from Michael K Biarnesen to Christopher J Silber et al. re Re: financial slides for Leiden meeting 2/2	ABBT0122953-59	No Objection
EK	2/1/2001	ABT-594 Descriptive Memorandum, February 2001	ABBT246793-801	No Objection
EL	2/2/2001	Project Review ABT-089 and ABT-594	ABBT0002314-469	No Objection
EM	2/2/2001	Draft Project Review: ABT 594, Agenda	ABBT0125335-37	No Objection
EN	2/2/2001	Email from Bruce McCarthy to Elizabeth Kowaluk re DSG	ABBT0163875-76	No Objection
EO	2/14/2001	Email from Bruce McCarthy to Michael K Biarnesen et al. re Re: Consideration of IV work with ABT-594	ABBT0123130	No Objection
EP	2/19/2001	Email from Bruce McCarthy to Chris Silber et al. re Scientific Strategy for ABT-594/NNR Tolerability	ABBT0115991-93	No Objection
EQ	2/26/2001	Email from Bruce McCarthy to Marleen Verlinden re ABT-594 Guest Speaker and Discussion	ABBT0163931	No Objection
ER	2/27/2001	Email from Marleen H Verlinden to Christopher J Silber re Re: ABT-594 partnering	ABBT0114639	No Objection
ES	2/27/2001	Email from Marilyn J Collicott to stherriault@rsi-nc.com enclosing M99-114 Investigation List and Early Terminations	ABBT238329-33	No Objection
ET	2/28/2001	Email from Bruce McCarthy to pandrews@sghms.ac.uk re Re: abbott visit	ABBT0163996-97	No Objection
EU	2/28/2001	E-mail from Marleen Verlinden re: Dr. Andrews	ABBT0556315	No Objection
EV	3/1/2001	Global Pharmaceutical Discovery, Internal Review, March 2001, Book #27, Michael Meyer, D47-W, AP9A-3	ABBT0024132-53	No Objection
EW	3/5/2001	ABT-594 / Pain Strategy Decision Analysis, Core Team Meeting - Minutes, 3/5/01	ABBT298380-85	No Objection
EX	3/6/2001	Pain Therapeutic Area Strategy/ABT-594 Decision Analysis, Decision Frame	ABBT0115871-76	No Objection
EY	3/7/2001	Abbott Portfolio Review, March 7-9, 2001	ABBT0048632-45	Poor Copy
EZ	3/7/2001	Portfolio Review Meeting, March 7-9, 2001	ABBT0118740-43	No Objection
FA	3/7/2001	E-mail from Bruce McCarthy re: Dr. Andrews meeting	ABBT0164139-40	Hearsay
FB	3/7/2001	Email from Bruce McCarthy to Elizabeth Kowaluk re Re: Draft Decision Frame for ABT-594/Pain Strategy DSG	ABBT297525-55	No Objection
FC	3/7/2001	Building a World of Opportunities Together - Development portfolio review kick-off	MCK00377-86	Hearsay

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
FD	3/8/2001	Email from Elizabeth Kowaluk to Marleen H Verlinden et al. re ABT-594/Pain Strategy DSG - 3/5 Meeting Minutes	ABBT298379-85	No Objection
FE	3/9/2001	Email from Paul Andrews to Bruce McCarthy re answers	ABBT0164141-201	Hearsay
FF	3/12/2001	Calendar Entry - Paul Andrews, PhD: ABT-594 Guest Speaker and Discussion	ABBT0022006-08	No Objection
FG	3/12/2001	Paul Andrews, PhD, Meeting Agenda	ABBT0556316	No Objection
FH	3/13/2001	Email from Michael Williams to Jeff Leiden re List of next steps from portfolio review	MCK00423-30	Hearsay
FI	3/19/2001	Confidential R&D Integration Update Discussion Document	MCK00348-76	Hearsay
FJ	3/28/2001	Email from Susan E Nunn to Judith S Brownell re update regarding M99-114	ABBT0081607	No Objection
FK	4/1/2001	ABT-594 Monthly Report for April, 2001	ABBT0000491-96	No Objection
FL	4/1/2001	Confidential Overview of Abbott R&D Fact Pack - April 2001	MCK00276-347	Hearsay
FM	4/10/2001	Email from Elizabeth Kowaluk to Keith F Hendricks et al. re Pharma Strategy Retreat on May 2-4	ABBT323300-05	No Objection
FN	4/23/2001	PowerPoint M99-114 Study Review	ABBT0001749-68	No Objection
FO	5/4/2001	E-mail from Jeff Drajesk with GPRD attachment	ABBT0114968-72	Incomplete
FP	5/4/2001	M99-114 Study Review	ABBT0184277-371	No Objection
FQ	5/4/2001	Email from Michael D Meyer to James Sullivan re ABT-594 Memo	ABBT335154	No Objection
FR	5/5/2001	Resource Allocation Across GPRD, Discussion Document	MCK00204-75	Hearsay
FS	5/6/2001	Email from Jessica Hopfield to Jeff Leiden re R&D Strategy Retreat Output	MCK00408-22	Hearsay
FT	5/10/2001	Email from James W Thomas to Yiming Zhang re 594	ABBT0080471-72	No Objection
FU	5/23/2001	Email from Thomas E Woidat to Michael K Biarnesen re Re: ABT-594 2001 Transition Budget; ABT-594 Transition Proposal	ABBT364494-496 ABBT0548527-34	Multiple Documents
FV	6/18/2001	Email from Judith S Brownell to Marilyn J Collicott et al. re RELEASE OF DATABASE, M99-114 (MC114A), ABT-594	ABBT239029	No Objection
FW	6/18/2001	Portfolio Analysis of 2001 Abbott Global Pharmaceutical Development Assets - June 18-20, 2001	MCK00014-108	Hearsay
FX	7/1/2001	ABT-594 Monthly Report for July, 2001	ABBT0000612-18	No Objection
FY	7/30/2001	Email from Elizabeth Kowaluk to Steve C Kuemmerle re ABT-594 DSG analysis - preview meetings	ABBT317214	No Objection
FZ	7/31/2001	Clinical Study Report No. R&D/01/171, A Randomized, Double-Blind, Placebo-Controller, Comparison of the Safety and Efficiency of ABT-594 to Placebo in subjects with Painful Diabetic Polyneuropathy (signed version)	ABBT0065982-78893	No Objection
GA	7/31/2001	Clinical Study Report No. R&D/01/171, A Randomized, Double-Blind, Placebo-Controller, Comparison of the Safety and Efficiency of ABT-594 to Placebo in subjects with Painful Diabetic Polyneuropathy	ABBT241331-560	No Objection
GB	8/6/2001	Email from Elizabeth Kowaluk to Bruce McCarthy	ABBT326352	No Objection
GC	8/21/2001	ABT-594 Pharma Executive Management Committee Review	ABBT0001974-2029	Incomplete Multiple Documents

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
GD	8/21/2001	PEC ABT-594 Decision Analysis	ABBT0165081-96	No Objection
GE	9/13/2001	Probability Assessment Worksheet: 9/13/01	ABBT127868.UR	No Objection
GF	9/27/2001	ABT-594 Proposal for additional Phase IIb study	ABBT0048402-33	No Objection
GG	10/1/2001	ABT-594 Monthly Report for October, 2001	ABBT0000758-63	No Objection
GH	10/5/2001	Email from Marilyn J Collicott to JanLips710@aol.com re Re: (no subject)	ABBT241303	No Objection
GI	10/9/2001	Email from Tamara L Garavalia to Linda M Fisher re ABT-594 Not Funded	ABBT0148334	No Objection
GJ	10/23/2001	DSG Highlights: October 2001	ABBT0515808-9	No Objection
GK	10/24/2001	Email from Philip M Deemer to Ake L Johansson re Update	ABBT246338-44	No Objection
GL	11/16/2001	Letter from Daphne Pals to Mr. Steve Blewitt re Research Funding Agreement dated as of March 13, 2001 Termination of ABT-594	ABBT0033833	Authentication / Hearsay (handwritten notes)
GM	6/7/2002	Email from Michael D Meyer to Christopher J Silber re DDC slides	ABBT0108742-79	No Objection
GN	6/13/2002	DDC: A-429202 Neuronal Nicotinic Receptor (NNR) Agonist, Discovery Development Candidate	ABBT0023982-24053	No Objection
GO	6/27/2002	Email from Bruce McCarthy to Marleen H Verlinden re Questions re goals	ABBT0546449-50	No Objection
GP	12/10/2002	GPRD PowerPoint Presentation	ABBT0105563-86	No Objection
GQ	11/14/2006	Letter from J. Christopher Jackson to Richard C. Abati re Constella Group Subpoena		Hearsay
GR	00/00/00	Probability Assessment Worksheet	ABBT0047907-08	No Objection
GS	00/00/00	Letter to M99-114 study cites	ABBT0082749	No Objection
GT	00/00/00	ABT-594 PowerPoint Slides (Development Plan)	ABBT0102966-68	No Objection
GU	00/00/00	Pathways and Pharmacology of Emesis	ANDR00033-92	Hearsay
GV	00/00/00	L. Klotz Notes	JH002974-75	Hearsay
GW	00/00/00	Initial Portfolio Prioritization	MCK00431-37	Hearsay
GX	00/00/00	Development Portfolio Overview	MCK00438-42	Hearsay
GY	00/00/2001	2001 Plan Key Statistics Pass II	ABBT0037544	Incomplete
GZ	00/00/2001	2001 APU Development Cost Summary	ABBT366059	No Objection
HA	11/8-9/2000	E-mail string from Bruce McCarthy	ABBT0110505-6	Hearsay Irrelevant
HB	11/30/2000	Email from Michael Biarnesen to Christopher Silber re 594 sales/cost estimate slide	ABBT0122385-86	No Objection
HC	1/23/2001	Project Status from Jim Tyree's Expanded Staff Meeting	ABBT0128117-18	No Objection
HD	2/13/2001	Email from Marilyn Collicott to stherriault@rsi-nc.com	ABBT242681-86	No Objection
HE	10/28/2000	Investigational New Drug (IND) Annual Report (Reporting Period October 29, 1999 - October 28, 2000)	ABBT236676-729	No Objection
HF	2/6/2001	Summary of Success Probabilities by Project and Franchise Portfolio Analysis (January 2001)	ABBT0012431-32	No Objection
HG	8/21/2001	ABT-594 Decision Analysis - Pharmaceutical Executive Management Committee Review	ABBT0022081-92	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
HH	10/10/2001	Email from Bruce McCarthy to Michael Biarnesen re ABT-594 Update	ABBT245657	No Objection
HI	3/5/2001	ABT-594 Decision Analysis - Core Team Meeting	ABBT329247-251	No Objection
HJ	5/25/2000	Letter from Marilyn Collicott to Michael Hoffstetter	ABBT242154	No Objection
HK	9/3/1999	Email from Christopher to Rosemarie Waleska re Advice	ABBT0159274	No Objection
HL	3/00/01	ABT-594 Monthly Report	ABBT0000451-56	No Objection
HM	10/19/2001	Email from Philip M. Deemer to Bruce McCarthy re: ABT-594 Call	ABBT245857	Hearsay
HN	5/00/00	Cholinergic Channel Modulation	ABBT0021817-860	No Objection
HO	10/10/2001	Email from Bruce McCarthy to Michael Biarnesen	ABBT245657-660	No Objection
HP	9/27/2001	ABT-594 - PEC Review Book: Proposal for additional study and background (nonstandard format)	ABBT113285.UR-315.UR	No Objection
HQ	7/6/2000	ABT-594 2001 Update, Clinical Studies	ABBT144619.UR-20.UR	No Objection
HR	Apr-99	ABT-773 Project Status Report	ABBT005056-63	No Objection
HS	5/1/1999	ABT-773 Project Status Report for May 1999	ABBT004844-50	No Objection
HT	Jun-99	Top 10 Issues	ABBT0017678-79	Incomplete
HU	8/1/1999	ABT-773 Project Status Report dated August 1999	ABBT0004627-36	No Objection
HV	3/16/2000	Email from Tim Vanbiesen to Elizabeth Kowaluk re ABT-773 Dosing Strategy Kick-off Meeting	ABBT305783-84	No Objection
HW	6/1/2000	ABT-773 Ketolide Antibiotic 2000 Strategic Marketing Plan dated June 2000	ABBT0570747-70	No Objection
HX	6/5/2000	ABT-773 Descriptive Memorandum dated May 2000	ABBT246466-71	No Objection
HY	7/4/2000	Email from Lynn Klotz to Stephen Blewitt re Kelotide Research Summary	JH003027-31	Hearsay
HZ	9/13/2000	Email from Gregor Bosco to Carol S. Meyer re ABT-773 Dev. Plan	ABBT0557552-57	No Objection
IA	11/1/2000	ABT-773 Descriptive Memorandum	ABBT0006648-52	No Objection
IB	11/1/2000	November 2000 - "Top" Issues	ABBT0017833	Hearsay
IC	11/20/2000	Email from Belinda Hightower to Phyllis KIncomplete Document or Bad Copy -- Documents for which only certain pages were designated or a better copy of that document is available. <u>Federal Rules of Evidence 1002 and 1003 aid re Clinical Hold</u>	ABBT0556812	Hearsay
ID	11/20/2000	Email from Jeanne M. Fox to John M. Leonard et al. re FDA Telephone Contact Report ABT-773	ABBT0558681-83	Hearsay
IE	11/27/2000	FDA Contact Report - ABT-773 End of Phase 2 Meeting	ABBT205257-59	Hearsay
IF	11/28/2000	Email from Jeanne M. Fox to Lawrence E. Roebel et al. re Executive Summary of ABT-773 End-of-Phase 2 Mtg w/FDA	ABBT0558150	Hearsay
IG	11/29/2000	Email from Jeanne M. Fox to Rod M. Mittag et al. re Slides for 12/5 Meeting	ABBT0556816-22	No Objection
IH	Dec-00	December 2000 Top Issues	ABBT0017554-55	Incomplete
II	12/5/2000	ABT-773 Portfolio Review	ABBT0577000-168	No Objection
IJ	1/1/2001	ABT-773 Monthly Report	ABBT214449	No Objection
IK	1/1/2001	January 2001 ABT-773 Project Status Report	ABBT222821-27	Hearsay

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
IL	2/1/2001	ABT-773 Monthly Report	ABBT0000387-99	Hearsay
IM	2/1/2001	ABT-773 Descriptive Memorandum dated February 2001	JH008153-58	No Objection
IN	2/12/2001	ABT-773 Update, [Monthly Report for [February 12, 2001]	ABBT0576828-71	No Objection
IO	2/12/2001	ABT-773 Update February 12, 2001	ABBT205042-46	No Objection
IP	2/12/2001	ABT-773 Update February 12, 2001	ABBT205047-87	No Objection
IQ	2/14/2001	Email from Jeanne M. Fox to James Steck re Studies to Meet Pediatric Rule Requirements	ABBT0568172	No Objection
IR	2/22/2001	Email from Eugene X. Sun to Stan Bukofzer re 773 Material	ABBT204959-5046	Hearsay
IS	3/1/2001	ABT-773 Monthly Report for March 2001	ABBT0000428-38	No Objection
IT	3/7/2001	Abbott Portfolio Review - March 7-9, 2001 re ABT-773	ABBT0013203-14	Poor Copy
IU	3/19/2001	ABT-773 Update March 19, 2001	ABBT228099-137	No Objection
IV	3/27/2001	Email from Thomas E. Woidat to William A. Brown re 773 Presentation	ABBT363844	No Objection
IW	3/31/2001	Email from Marleen H. Verlinden to Eugene X. Sun re ABT-773	ABBT0571202-03	No Objection
IX	Apr-01	ABT-773 April Update	ABBT0000468-78	Hearsay
IY	4/12/2001	ABT-773 Ph III Decision Project	ABBT116508ur-17ur	No Objection
IZ	4/12/2001	Email from Thomas E. Woidat to Jennifer Dart re: Portfolio Analysis - Update with APU budgets	ABBT357615-20	No Objection
JA	5/2/2001	Memo from Jeff Leiden to Stan Bukofzer, John Leonard and Eugene Sun re: First Call Report	ABBT0573479-83	Hearsay
JB	6/17/2001	Email to Hendricks, et al. re: Final copy of 773 decision analysis planned presentation	ABBT224941-83	No Objection
JC	6/20/2001	Email from Carol S. Meyer to Ake L. Johansson, et al., re: ABT 773 Taisho/Abbott Meeting - June 26th	ABBT229367-9448	No Objection
JD	6/22/2001	Email from Stan Bukofzer to Jeanne M. Fox re: Final copy of 773 decision analysis planned presentation	ABBT203851-94	No Objection
JE	7/1/2001	ABT-773 Monthly Report	ABBT0000589-98	No Objection
JF	7/23/2001	ABT-773 Decision Analysis Core Team	ABBT103191.UR-244	No Objection
JG	9/27/2001	Email from Carol S. Meyer to Stan Bukofzer re: ABT 773 2002 Plan Powerpoint slides	ABBT229605-09	No Objection
JH	Oct-01	ABT-773 Monthly Report	ABBT0000726-35	No Objection
JI	10/8/2001	Abbott Portfolio Review 2002 Plan	ABBT228798-837	No Objection
JJ	12/14/2001	Email from John M. Leonard to Stan Bukotzer re: December 12 PEMC Meeting Minutes	ABBT209485-88	No Objection
JK	12/17/2001	Email from Thomas J. Lyons to Stan Bukotzer re: JH Annual Progress Report & Y/E LBE	ABBT0009384-88	No Objection
JL	1/3/2002	Email from Stan Bukofzer to John M. Leonard, Eugene Sun re: 773 presentation	ABBT220928-53	No Objection
JM	1/3/2002	Email from Eugene X. Sun to John M. Leonard, et al., re: 773 memo to Miles	ABBT231340-42	No Objection
JN	1/4/2002	Email from Stan Bukofzer to Jeff M. Leiden, et al., re: ABT 773 Memo	ABBT220660-72	No Objection
JO	1/7/2002	Letter from Jeff Leiden, John Leonard to Miles White re: package with key issues	ABBT0559668-70	No Objection
JP	1/7/2002	Letter from Eugene Sun, Stan Bukofzer to Miles White re: package with key issues	ABBT207773-75	No Objection
JQ	2/1/2002	ABT-773 Monthly Report	ABBT0000918-927	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
JR	2/2/2002	E-mail from Tina Ventura re: 773 communications strategy	ABBT229753-70	No Objection
JS	2/4/2002	Email from Jeff M. Leiden to Thomas J. Lyons re: 2002 773 LBE	ABBT224544-51	No Objection
JT	2/9/2002	Email from Stan Bukofzer to Jeff M. Leiden re: ABT 773 documents requested	ABBT225309-23	No Objection
JU	7/11/2002	Email from Stan Bukofzer re ABT-773 Communication	ABBT203446-48	No Objection
JV	9/10/2002	ABT-773 Lessons Learned Overview	ABBT222829-42	No Objection
JW	Jul-04	June Highlights Memo (global outlicensing)	ABBT248011-12	No Objection
JX	00/00/00	Abbott Compound Development Summaries	ABBT0094631-61	No Objection
JY	3/8/2000	ABT-773 Clinical Developmnet Optimization: Analhsis of a 150mg Dose for Bronchisits and a 5-day Course of Therapy for CAP	ABBT111376.UR-427.UR	No Objection
JZ	7/9/2001	Email from Steve Kuemmerle to Stan Bukofzer re ABT-773 Analysis	ABBT210063-98	No Objection
KA	6/11/2003	Pain Therapeutics Program Overviews (PEC Meeting)	ABBT0102860-71, 916-19	Incomplete, Irrelevant
KB	7/29/2003	Kowaluk e-mail with attached pain portfolio profile re: ABT-894	ABBT323817-30	No Objection
KC	5/1/2005	ABT-894 Scientific Advistory Counsel Doc	ABBT0080815-34	No Objection
KD	1/12/2006	Suzanne Lebold e-mail string re: recommend no ABT-594 outlic due to 894	ABBT371710-15	No Objection
KE	1/12/2006	Email from Kevin Constable to Suzanne Lebold	ABBT279668-73	Hearsay
KF		Description of Press Release: ABT-894 PhII Announcement Press Release at: http://www.neurosearch.com/Default.aspx?ID=4080&M=News&PID=22571&NewsID=15415		Hearsay Irrelevant
KG		Description of Part 2: Neuroscience 894 description at: http://www.neurosearch.com/Default.aspx?ID=120		Hearsay
KH		Description of Part 3: Neuroscience NNR description at: http://www.neurosearch.com/Default.aspx?ID=1574		Hearsay
KI		Description of Part 4: Neuroscience/Abbott collaboration description at: http://www.neurosearch.com/Default.aspx?ID=93		Hearsay Irrelevant
KJ		Email from Lise Loberg to William Bracken re ABT-894 IND	ABBT0155807	Irrelevant
KK	12/14/1998	Email from Bruce McCarthy to David Ross et al re Letter to the FDA	ABBT0116076-77	No Objection
KL	6/23/1999	Alternative Funding Initiatives	AL000120-131	Lack of Authentication, Hearsay
KM	1/12/2000	Email from Thomas Freyman to Philip Deemer	ABBT246802	No Objection
KN	1/27/2000	Email from Scott Hartz to Stephen Blewitt re Abbott	JH003563	Hearsay
KO	2/7/2000	Email from Philip Deemer to Erik Zimmer et al re Hancock	ABBT245855	No Objection
KP	3/7/2000	Email from Stephen Blewitt to Steve Cohen re Research and Development Transaction	AL000132-34	Hearsay
KQ	4/2/2000	Email from Stephen Blewitt re Abbott	JH001707-24	Hearsay, Lack of Authentication
KR	4/5/2000	Email from Robert Weiland to Rosemarie Waleska et al re Hancock R&D Funding	ABBT246414-15	No Objection
KS	6/2/2000	Email from Lynn Klotz to Stephen Blewitt re my cv and thoughts about strategy	JH003089-100	Hearsay

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
KT	6/7/2000	Email from Philip Deemer to Steve Cohen re John Hancock/Abbott Funding Collaboration	AL000198-99	No Objection
KU	6/20/2000	Email from Lynn Klotz to Stephen Blewitt re Preliminary Abbott basket analysis	JH003080-90	Hearsay
KV	7/16/2000	Email from Philip Deemer to Stephen Blewitt	JH004813	Hearsay
KW	7/24/2000	Email from Frank Loughery to Philip Deemer et al re Hancock Deal	AL002064	No Objection
KX	7/27/2000	Email from Philip Deemer to Stephen Blewitt	JH004780-812	Irrelevant, Hearsay
KY	7/28/2000	Email from Lynn Klotz to Stephen Blewitt re Abbott interview writeup	JH002973-79	Hearsay
KZ	8/4/2000	Email from Philip Deemer to Barbara Powell re John Hancock Slide describing John Hancock company	AL000099-102	No Objection
LA	8/14/2000	Email from Steve Cohen to Julia Bouffard et al re John Hancock/Miles meeting	AL000137	No Objection
LB	8/14/2000	Email from Philip Deemer to Steve Cohen re contract to Hancock that Brian wants Arthur to see first	AL000238	No Objection
LC	8/17/2000	Email from Philip Deemer to Stephen Blewitt re Draft Research Funding Agreement	AL000138-75	No Objection
LD	8/25/2000	Email from Philip Deemer to John Leonard re Hancock	AL000983	No Objection
LE	9/18/2000	Email from Brewster Lee to Deborah Young et al re Abbott/Hancock - Memo re Research Funding Agreement	JH003342-46	Hearsay
LF	9/21/2000	John Hancock Purchase Recommendation (Abbott)	JH001203-20	No Objection
LG	10/10/2000	Minutes from Finance Committee Meeting	JH005551-53	Hearsay
LH	10/16/2000	PPD Plan Review	ABBT0155579-80	No Objection
LI	10/17/2000	Email from Daphne Pals to Brewster Lee et al re Research Funding Agreement	JH004385-461	No Objection
LJ	10/27/2000	Email from Philip Deemer to Steve Blewitt	JH000778-86	Multiple Documents
LK	11/16/2000	Email from Kevin Tormey to Philip Deemer et al re Research Funding Agreement	AL000790-836	Hearsay
LL	11/16/2000	Draft Redline - Research Funding Agreement by and between Abbott Lab and John Hancock	JH005232-71	Hearsay
LM	11/21/2000	Email from Daphne Pals to Amy Weed et al re Exhibit for Development Plans	JH004980-88	No Objection
LN	11/30/2000	MMPI Working Group Meeting Minutes	ABBT0045277-78	No Objection
LO	12/1/2000	Fax from Philip Deemer to Arthur Higgins re Hancock	AL001946	No Objection
LP	12/5/2000	Minutes from the D46R Senior Staff Meeting	ABBT0140316	No Objection
LQ	12/15/2000	Memorandum from Steve Cohen to Dr. Jeffrey Leiden et al re 2001 Plan	ABBT0007157-74	No Objection
LR	12/21/2000	2001 Plan Assumption Memo - Pass III	ABBT112985.UR-992, 112995-999, 113015-018, 113026-3029.UR	No Objection
LS	1/11/2001	MMPI Working Group Meeting Minutes - Objective: Overall Project Update	ABBT0045264-69	No Objection
LT	1/22/2001	Forecast Methodology and Assumptions Early Oncology Pipeline Portfolio Analysis January 2001	ABBT0012938-69	No Objection
LU	1/24/2001	Fax from Daphne Pals to Kevin Tormey and Brewster Lee enclosing draft Research Funding Agreement	JH006360-404	Authentication / Hearsay (handwritten notes)

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
LV	1/25/2001	Email from Elizabeth Koweluk to Steve Kuemmerie et al re Summary of Success Probabilities	ABBT301935-41	No Objection
LW	1/26/2001	Analgesia Venture 2001 Plan - Revised 1/26/01 to John Leonard et al	ABBT0503356-62	Incomplete Authentication / Hearsay (handwritten notes)
LX	1/26/2001	Analgesia Venture 2001 Plan - Revised 1/26/01 to John Leonard et al	ABBT144630.UR-46	Incomplete
LY	1/30/2001	John Hancock Life Insurance Company Research Funding Agreement - Prepared from Draft of 1/23/01	ABBT0158779-92	No Objection
LZ	2/15/2001	Email from Philip Deemer to Chris Turner re Exhibits	ABBT246062-63,123,28, 31,34,37,40,43,46,49-51 ABBT246076-91, ABBT246064-69, ABBT246132-33,52-54, ABBT246121-22, ABBT246070-75, ABBT246117-20, ABBT246092-116,124, 126-27,129-30,135-36, 138- 39,141-42,144-45, 147-48	No Objection
MA	3/1/2001	Memorandum from Xavier Frapaise to John Arnott et al re Development Portfolio Review Meeting - March 7-9	ABBT0164029-31	No Objection
MB	3/2/2001	Memorandum from Matt Russell to Bob Funck et al re 2001 Plan Final Reference Package	ABBT0037509-608	No Objection
MC	3/7/2001	Portfolio Review Meeting - March 7-9, 2001	ABBT0177980-83 ABBT0177974-77	No Objection
MD	3/12/2001	Email from William Adams to Stephen Blewitt et al re final clean and redlined versions of the Research Funding Agreement.	JH010033-142	No Objection
ME	3/13/2001	J. Hancock Research Funding Agreement for Abbott: Executive Summary of March 13, 2001 Agreement	AL002066-69	No Objection
MF	4/1/2001	Summary of R&D Projects - 2001 April Update	ABBT140276-77.UR	No Objection
MG	4/1/2001	Email from Elizabeth Kowaluk to Steve Kuemmerle et al re Success Probabilities	ABBT317221-39	No Objection
MH	4/12/2001	MMPI Working Group Meeting Minutes	ABBT0026337-38	No Objection
MI	4/12/2001	MMPI Monthly Meeting Agenda Objectives: To Review MMPI Project Status	ABBT0045243-45	No Objection
MJ	4/20/2001	Portfolio Analysis of 2001 Abbott Global Pharmaceutical Development Assets	ABBT127558.UR-652.UR	No Objection

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
MK	4/26/2001	Email from Philip M. Deemer to Ron Gerlach re John Hancock Royalty Scenario	ABBT245877-79	No Objection
ML	4/27/2001	Portfolio Analysis of 2001 Abbott Global Pharmaceutical Development Assets, Addendum: Use of Productivity Index in Portfolio Selection	ABBT326405-10	No Objection
MM	5/1/2001	"Risks in New Drug Development: Approval Success Rates for Investigational Drugs"	CRA00113-23	Hearsay
MN	5/20/2001	Global Pharmaceutical Research & Development, 2001 April Update, Dr. Jeff Leiden Follow-Up Package	ABBT0037615-16	No Objection
MO	5/20/2001	Email from Perry D. Nisen to Azmi A. Nabulsi re MMPI	ABBT0063636	No Objection
MP	5/31/2001	Email from Diane L. D'Amico to Lise I. Loberg re MMPI Activities	ABBT0059672	No Objection
MQ	6/18/2001	Email from Thomas Woidat to Kenneth Stiles re Terminated Development Projects (Draft)	ABBT352510-15	No Objection
MR	6/27/2001	Email from John Leonard to Vaseern Iftekhar et al re Terminated Development Projects	ABBT334140-45	No Objection
MS	7/29/2001	Email from Robert Funck to Thomas Lyons et al re Hancock - 2002	ABBT0008946-48	No Objection
MT	8/22/2001	Email from Philip M. Deemer to Ake L. Johansson re Executive Briefing, Global Licensing and Business Development	ABBT246374-409	No Objection
MU	8/27/2001	Email from Philip M. Deemer to Ake L. Johansson re Update of Priorities	ABBT246324-28	Hearsay
MV	9/28/2001	Email from Denise L. Carlson to Fusako H. Bowering re Template for Outlicensing Update	ABBT245788-805	No Objection
MW	11/9/2001	Memo from John M. Leonard to Jeff Leiden re Monthly Highlights - October 2001	ABBT0003478-81	No Objection
MX	11/26/2001	Letter from Tom Lyons to Steve Blewitt re Research Funding Agreement dated as of March 13, 2001, 2002 Preliminary Annual Research Plan	JH000787-802	No Objection
MY	12/6/2001	Memo from John M. Leonard to Jeff Leiden re Monthly Highlights - November 2001	ABBT0003473-77	No Objection
MZ	12/18/2001	Letter from Tom Lyons to Steve Blewitt re Research Funding Agreement dated as of March 13, 2001, 2001 Program Status Report and Related Cost Summary	JH001065-68	No Objection
NA	12/20/2001	Handwritten Note with various attachments	ABBT0007038-54	No Objection
NB	12/13/2001	Memo from Philip M. Deemer to Pamela Demain re Licensing Opportunities	ABBT246490-92	Hearsay
NC	2/13/2002	Memo from James L. Tyree to Jeff Leiden re January 2002 Highlights	ABBT247161-63	No Objection
ND	3/1/2002	Returns on R&D for 1990s New Drug Introductions	CRA00070-108	Hearsay
NE	4/15/2002	Email from John M. Leonard to Thomas J. Lyons et al. re Hancock Response	ABBT225709-10	No Objection
NF	4/22/2002	Email from Jennifer L. Baltic to Thomas J. Lyons et al. re Update Hancock Info.	ABBT152426.UR-27	No Objection
NG	5/30/2002	2002 Update, Global Pharmaceutical Research & Development	ABBT0011680-27	No Objection
NH	9/23/2002	Email from Gayle A. Kirkpatrick to Suzanne Lebold re Status of JH Compounds/Divestment Activities	ABBT334838-41	No Objection
NI	10/28/2002	"The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics 22 (2003) 151-185	CRA00035-69	Hearsay

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
NJ	11/7/2002	Memo from James L. Tyree to Jeff Leiden re October 2002 Highlights; Tyree memo dated 4/7/03 re March 2003 highlights; Leonard memo dated 2/13/04 re January 2004 highlights; Tyree memo dated 6/16/04 re May 2004 highlights; Poulos memo dated 8/15/05 re July 2005 highlights; Poulos memo dated 9/12/05 re August 2005 highlights	ABBT0518029-34, ABBT336134-35, ABBT103633.UR, ABBT103643.UR, ABBT104009.UR-10.UR, ABBT336155, ABBT336157, ABBT352599-04	Multiple Documents
NK	12/20/2002	Letter from Tom Lyons to Steve Blewitt re Research Funding Agreement dated as of March 13, 2001, (a) 2002 Program Status Report and Related Cost Summary, (b) 2003 Preliminary Annual Research Plan	AL001469-79	Authentication / Hearsay (handwritten notes)
NL	1/30/2003	Email from Thomas J. Lyons to Jeff M. Leiden re John Hancock Update	ABBT0007586-89	No Objection
NM	7/7/2003	New Drug Development: Estimating Entry from Human Clinical Trials	CRA00001-24	Irrelevant, Hearsay
NN	11/12/2003	Letter from James L. Tyree to Stephen J. Blewitt re Research Funding Agreement Between <u>Abbott Laboratories and John Hancock dated March 13, 2001</u>	JH001283-90	No Objection
NO	4/12/2004	Letter from Stephen Blewitt to James L. Tyree re Research Funding Agreement by and between <u>Abbott Laboratories and John Hancock dated as of March 13, 2001</u>	JHII011883-90	Improper Opinion
NP	5/6/2004	Letter from Brian Davis to Lawrence Desideri	JHII011366-75	Improper Opinion, Hearsay
NQ	5/8/2004	StoneTurn invoices from April 5, 2004 through April 1, 2005	JHII021505-25	Hearsay
NR	6/30/2004	Choate, Hall & Stewart Bills re Audit	JHII021714-39	Hearsay
NS	7/28/2004	Fax Transmittal Letter from Karen Collari Troake to Lawrence R. Desideri re Inspection and Audit	ABBT0000117-23	Hearsay Improper Opinion
NT	8/10/2004	Letter from Karen Collari Troake to Lawrence r. Desideri re Research Funding Agreement By and Between <u>Abbott Laboratories and John Hancock dated March 13, 2001</u>	JHII011334-37	Hearsay Improper Opinion
NU	8/26/2004	Email from Chris Martinez to Michelle Campbell	ABBT0126620-21	Hearsay
NV	8/26/2004	Email from Chris Martinez to Michelle Campbell	ABBT0126622	No Objection
NW	8/31/2004	Email from Chris Martinez to Michelle Campbell re John Hancock Audit	ABBT0126635-39	Hearsay
NX	9/28/2004	Email from Michelle L. Campbell to Chris Martinez re Status of Documents Available for Review <u>re John Hancock Audit</u>	ABBT0000255-56, ABBT0126645-47	Hearsay
NY	10/6/2004	Email from Chris Martinez to Michelle Campbell re Status of documents available for review	ABBT0126645-47	Hearsay
NZ	10/27/2004	Letter from Karen Collari Troake to Lawrence r. Desideri re Research Funding Agreement By and Between <u>Abbott Laboratories and John Hancock dated March 13, 2001</u>	ABBT0000136	Hearsay
OA	11/10/2004	Letter from Brian Davis to Stephen D'Amore	JHII011346-48	Hearsay Improper Opinion

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
OB	12/8/2004	Email from Karen Collari Troake to Stephen D'Amore	ABBT0000151-54	Hearsay
OC	12/10/2004	Letter from Stephen Blewitt to James L. Tyree re Research Funding Agreement by and between Abbott Laboratories and John Hancock dated as of March 13, 2001	JHII011897-11899	Hearsay Improper Opinion
OD	1/4/2005	Email from Stephen D'Amore to Michelle Campbell re John Hancock/Abbott	ABBT0126684-87	Hearsay
OE	1/4/2005	Email from Deirdre Daesen to Steven McCormack et al. re Abbott - Impairment Amount	JHII011167-68	Hearsay
OF	1/10/2005	Global Pharmaceutical Research & Development, Hancock Collaboration, Spending by Program Chart	ABBT148376.UR, ABBT148382.UR, ABBT148379.UR, ABBT148381.UR, ABBT__0306.UR [?], ABBT0008528-30, ABBT348223, ABBT0004600	Incomplete; Hearsay Lack of Authentication Multiple Documents
OG	1/20/2005	Email from Chris Martinez to Michelle L. Campbell re Copies of Documents	ABBT0126734	Hearsay
OH	1/26/2005	Email from Michelle L. Campbell to Mark Hair re Copies of Documents Flagged Today	ABBT0126490-92	Hearsay
OI	1/26/2005	Email from Michelle L. Campbell to Kenneth A. Wittenberg re Copies of Documents Flagged Today - Privileged and Confidential	ABBT0126767-71	Hearsay
OJ	1/26/2005	Letter from Brian Davis to Stephen D'Amore	JHII011360-62	Hearsay Improper Opinion
OK	1/28/2005	Letter from Brian Davis to Stephen D'Amore	ABBT0000169-72	Hearsay Improper Opinion
OL	2/10/2005	Email from Brian A. Davis to Stephen V. D'Amore re Abbott/Hancock Audit Timing	ABBT0000175-81A	Hearsay Improper Opinion
OM	2/23/2005	Email from Stephen D'Amore to Michelle Campbell	ABBT0126964-65	Hearsay
ON	00/00/00	John Hancock contract compliance inspection of Abbott Records related to the March 13, 2001 Research Funding Agreement	JHII21600-06	Hearsay
OO	3/14/2005	Medical Products Group Portfolio Management Process	ABBT269161-210	Irrelevant
OP	3/15/2005	Email from Michelle Campbell to Mark Hair	ABBT0000280-84	Hearsay
OQ	3/18/2005	Email from Mark hair to Michelle L. Campbell re John Hancock - Abbott Audit Documentation	ABBT0000277-79	Hearsay
OR	3/22/2005	Email from Mark Hair to Michelle L. Campbell re Abbott Audit Documentation	ABBT0000273-76	Hearsay
OS	3/23/2005	Email from Mark Hair to Michelle L. Campbell re John Hancock Audit	ABBT0126973	Hearsay

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
OT	3/25/2005	Email from Michelle L. Campbell to Mark Hair re John Hancock Audit	ABBT0000270-71	Hearsay
OU	3/29/2005	Email from Stephen D'Amore to Brian Davis	ABBT0000210-14	Hearsay Improper Opinion
OV	3/29/2005	Email from Michelle Campbell to Mark Hair	ABBT0000267-68	Hearsay
OW	4/1/2005	Letter from Stephen Blewitt to James L. Tyree re Research Funding Agreement by and between Abbott Laboratories and John Hancock dated as of March 13, 2001	JH11011911-17	Hearsay Improper Opinion
OX	11/7/2005	Abbott Pharmaceutical R&D Metrics Analysis	ABBT248441-547	Irrelevant
OY	1/1/2006	2006 Portfolio Sales Data	ABBT248659-929	Irrelevant, Bad Copy
OZ	1/20/2006	Letter from Suzanne A. Lebold to Stephen J. Blewitt re Research Funding Agreement Between Abbott Laboratories and John Hancock dated March 13, 2001	ABBT0026105-16	No Objection
PA	3/23/2006	PPG R&D Review	ABBT0047220-88	No Objection
PB	7/1/2006	Article entitled A Safer Strategy: Investing in Biotech Stocks is a Risky Business, But There's Safety (As Well As Big Rewards) In Numbers	CRA00110-12	Hearsay Incomplete Irrelevant
PC	11/20/2007	Letter from Suzanne Lebold to Stephen Blewitt re Research Funding Agreement Update		No Objection
PD	00/00/00	Project Development Timelines for ABT-518, 594, 773 and 492	ABBT0003362-65, ABBT0003369, ABBT0003418, ABBT299147-56, ABBT299158 ABBT299288-97, ABBT220442-559	Incomplete
PE	00/00/00	Abbott Laboratories PPD R&D Alternative Financing Analysis John Hancock Funding Scenarios	ABBT0006861-64	Authentication / Hearsay (handwritten notes)
PF	00/00/00	80% Power Curve for Varying Effect Size for Neuropathic Pain Based on M98-833 and Gabapentin Results	ABBT0051885-88	No Objection
PG	00/00/00	Internal memorandum from Steve Cohen to Jeff and Arthur attaching Hancock package with three additional schedules	ABBT006748-68	No Objection
PH	00/00/00	Initial Portfolio Prioritization	ABBT0155581-87	Hearsay
PI	00/00/00	Growing and Enhancing World-Class Global Research and Development at Abbott, New Organizational Plan Roll-Out PowerPoint Presentation	ABBT0162922-46	No Objection
PJ	00/00/00	Memo from Azmi to Jim re Project Review	ABBT0507866	No Objection
PK	00/00/00	2001 APU GPRD, Hancock Deal	ABBT148440.UR ABBT148555.UR ABBT148543.UR	Incomplete

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
PL	00/00/00	2006 LRP Forecast Submission Workbook	ABBT299286-97	Irrelevant
PM	00/00/00	Memorandum To File re Abbott Laboratories ("Non-Recourse")	JH001103-04	Hearsay
PN	00/00/00	Handwritten note with attached Royalty Flowcharts	JH002250-96 JH002298-302	Hearsay Lack of Authentication/Foundation
PO	00/00/00	Nominal and Expected Sales Forecast	JH002314-17	Hearsay Lack of Authentication/Foundation
PP	00/00/00	John Hancock Document Index	JHII021526-94	Incomplete, Hearsay
PQ	00/00/00	John Hancock - Files from Document Index Flagged to be Copied and Not Received by StoneTurn	JHII021595-96	Incomplete, Hearsay
PR	00/00/00	John Hancock Activity/Communication Log Between MH of StoneTurn Group & Abbott Personnel ranging from 1/25/05 - 3/28/05	JHII021599	Hearsay
PS	00/00/00	John Hancock contract compliance inspection of Abbott Records related to the March 13, 2001 Research Funding Agreement	JHII021600-06	Hearsay
PT	00/00/00	Initial Portfolio Prioritization	ABBT0155602-08	Hearsay
PU	00/00/2001	Division Incentive Plan Goals - 2001 DIP	ABBT354864-65	Irrelevant
PV	8/19/04 - 7/31/05	Choate, Hall & Stewart Bills re Audit	JHII021826-945	Hearsay Lack of Authentication/Foundation
PW	5/13/2001	ASCO News Release - "Nearly 25,000 Cancer Specialists Meet in San Francisco For ASCO Annual Meeting"		Hearsay
PX	12/31/2002	PR Newswire - Abbott Laboratories Receives FDA Approval Earlier Than Anticipated for HUMIRA (TM) (adalimumab) for the Treatment of Rheumatoid Arthritis (RA)		Hearsay
PY	9/15/2004	Non-Use Agreement between Hancock and Abbott		Irrelevant
PZ	8/29/2005	Non-Use Agreement between Hancock and Abbott		Irrelevant
QA	12/31/2006	Abbott Form 10-K for the year ended December 31, 2006		Irrelevant
QB	1/19/2007	Report of William R. Fairweather, Ph.D., with attached exhibits, and workpapers produced in discovery		Hearsay Improper Opinion
QC	6/1/2007	Summary of Anticipated Expert Testimony of Dr. Barry I. Gold, with attached exhibits, and workpapers produced in discovery		Hearsay Improper Opinion
QD	11/5/2007	www.abbott.com.htm		Irrelevant
QE	11/5/2007	http://www.abbott.com/global/url/pressRelease/en_US/60.5.5/Press_Release_0537.htm		Irrelevant Bad Copy

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
QF	11/5/2007	http://www.abbott.com/global/url/content/en_US/60.15:15/feature/Feature_0030.htm		Irrelevant
QG	11/5/2007	Video on "How NNRs Work" at http://www.abbott.com/global/url/content/en_US/60.15:15/feature/Feature_0030.htm		Irrelevant
QH	12/3/2007	Updated Expert Report of Alan Friedman with exhibits		Hearsay Improper Opinion
QI	00/00/00	AICPA Practice Aid Series, Assets Acquired in a Business Combination to be Used in Research and Development Activities: A Focus on Software, Electronic Devices, and Pharmaceutical Industries		Hearsay Irrelevant
QJ	00/00/00	List of Key Personnel		No Objection
QK	00/00/00	Neuroscience and Pain by James Sullivan		No Objection
QL	00/00/00	Documents Requested to be Produced by Abbott for Audit Purposes in December 2004		Hearsay
QM	3/30/2007	Notice of Deposition for Abbott Laboratories		Hearsay
QN	5/29/2007	Letter from Russell J. Edelstein to Ozge Guzelsu Enclosing List of Documents Relied Upon by Dr. Gold		Hearsay
QO	1/29/2001	Letter from Richard Ashley of McKinsey & Company to Joe Nemmers of Abbott	MCK00681-82	Hearsay
QP	2/24/2001	Letter from Jessica Hopfield of McKinsey & Company to Jeffrey Leiden	MCK00683-84	Hearsay
QQ	5/8/2000	Memorandum from Steve Blewitt to Messrs. Aborn, D'Alessandro, DeCiccio, Hartz, and Nastou	JH 002423-29	Hearsay Multiple Documents
QR	00/00/00	EITF Abstracts	JHII 021463-95	Lack of Authentication/Foundation Hearsay
QS	00/00/00	GPRD APU - J. Leiden Questions	ABBT037609-14	Authentication / Hearsay (handwritten notes)
QT	00/00/00	Drugs and Related New Indications in Development	AUDIT 000042	No Objection
QU	00/00/00	Charts - Power to Demonstrate Equivalence in a Phase 3 Trial	AUDIT 00517-19	Incomplete Irrelevant
QV	3/21/2002	ABT-492 Strategy Analysis: SG&A Assessment Review	AUDIT 001236-51	Irrelevant
QW	00/00/00	Candidates Delivered to Development	AUDIT 001687-89	Irrelevant
QX	2/11/2003	Letter from Ake Johansson to Eli Lilly Pharmaceuticals	AUDIT 002571-72	Hearsay Irrelevant Lack of Authentication/Foundation
QY	2/5/2003	Email from Mary Clare DeLuca to Sam Hawgoog	AUDIT 002573-74	Irrelevant

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
QZ	2/14/2003	Out-license Anti-Infective Compounds, Board Document	AUDIT 002578-79	No Objection
RA	12/16/2002	Fax from Mylene Salamero to Tom Hurwich	AUDIT 002597-98	Irrelevant Incomplete
RB	12/10/2002	Email from Ake Johansson to Jeff Leiden	AUDIT 002599-601	Irrelevant
RC	1/15/2003	Email from Mylene Salamero to Ake Johansson	AUDIT 002603	Irrelevant
RD	1/10/2003	Memo from Ake Johansson to J. Leiden	AUDIT 002604-08	Irrelevant, Hearsay
RE	1/8/2003	Email from Mylene Salamero to gtibbitts@elitra.com	AUDIT 002609	Irrelevant
RF	00/00/00	Handwritten notes	AUDIT 002610	Authentication / Hearsay (handwritten notes) Irrelevant
RG	00/00/00	Elitra Pharmaceuticals	AUDIT 002611	Authentication / Hearsay (handwritten notes) Irrelevant
RH	12/00/02	A-319210.0 A Novel Fluoroketolide Antibiotic	AUDIT 003172-237	Hearsay Irrelevant
RI	12/10/2002	John Hancock Summary: ABT-773	AUDIT 003254	Irrelevant
RJ	00/00/00	Project ODIN - Contract Summary of Action Items by Date	AUDIT 003306	Authentication / Hearsay (handwritten notes) Irrelevant
RK	00/00/00	Project ODIN - Divestiture of ABT-773 - Outcomes Summary	AUDIT 003307	Authentication / Hearsay (handwritten notes) Irrelevant
RL	5/20/2004	Handwritten Notes - MAY PEC	AUDIT 008167-69	Authentication / Hearsay (handwritten notes) Irrelevant
RM	00/00/00	Email from Mary to Wendy Hinz re M96-594 Draft 1.1	AUDIT 008331-33	Irrelevant
RN	00/00/00	M96-594, Subjects with Treatment Emergent Serious Adverse Events (All Randomized Subjects)	AUDIT 008335-43	Irrelevant
RO	5/21/2003	Global Pharmaceuticals Business Strategy	AUDIT 011515-40	Irrelevant
RP	4/14/2004	CMR International Success Rates	ABBT308584-645	Lack of Authentication/Foundation Hearsay Improper Opinion Irrelevant

John Hancock's List of Objected To Trial Exhibits
January 28, 2008

Trial Exhibit No.	Date	Description	Bates Nos.	Abbott's Objections
RQ	11/20/2003	Letter from James Tyree to Stephen Blewitt		Settlement Hearsay
RR	5/6/1999	Letter from Lynn Klotz to Stephen Blewitt and Dana Donovan with draft consulting agreement	JH 001699-1701	Hearsay Irrelevant
RS	11/21/2002	ABT-510 Monthly Report, Post Oct 19	ABBT0007270-72	Hearsay
RT	11/30/2007	Updated Summary of Anticipated Expert Testimony of Dr. Barry I. Gold		Hearsay Improper Opinion
RU	11/15/2006	Letter from Suzanne Lebold to Stephen Blewitt		No Objection
RV	3/26/2007	Revised Notice of Deposition of Abbott Laboratories		Hearsay
RW	2/6/2006	John Hancock's Objections and Responses to Abbott Laboratories' First Set of Interrogatories		Hearsay
RX	3/21/2001	Email from Thomas Woidat to Mike Higgins re Proposed APU Target Adjustments	ABBT364018-20	No Objection
RY	00/00/00	Cholinergic Channel Modulator (ABT-594) 2000 AGU Development cost Summary	ABBT338037, ABBT0116305, ABBT366059	Multiple Documents Incomplete
RZ	00/00/00	Abbott-John Hancock Funding Collaboration	AL000059-76	No Objection
SA	10/8/2001	ABT-594 Decision Analysis, Update: ABT-594 Intermediate Dose (75-125 MCG) Ph. IIb Study	ABBT0165097-104	No Objection
SB	00/00/00	Various Documents	ST-AUDIT 00001-42765	Hearsay Multiple Documents
SC	00/00/00	John Hancock Portfolio Summary, Revenue Recognition, 2003 Plan - Plan Book	JHII 021597	Hearsay
SD	4/20/2004	Email from Kenneth Wittenberg to Amy Potthoff, et al re Meeting re Hancock audit	ABBT0036399 ABBT0008949	No Objection
SE	1/21/2005	Email from Stephen D'Amore to Michelle Campbell re Documents Request in July 2004 and Re- <u>Requested on December 17, 2004</u>	ABBT0126735-36	No Objection
SF	8/6/2004	Email from Jim Wendrickx to Michelle Campbell re Invoices	ABBT0126614-15	Hearsay
SG	3/23/2005	Email from Stephen D'Amore to Kenneth Wittenberg	ABBT0126979-82	Hearsay
SH	00/00/00	StoneTurn - Time sheet Report (Timeslips System through 9/30/05)	JHII021501-04	Hearsay
SI	00/00/00	Documents that were received by StoneTurn but not identifiable or previously included in the <u>Document Index.</u>	JHII021598	Hearsay
SJ	3/27/2005	Special Counsel Invoices to Abbott	ABBT0005098-112	Multiple Documents Hearsay
SK	1/16/2001	Email from Marilyn Collicott to JSHCANZENBACH@rsi-nc.com@internet re meeting today	ABBT242693-99	No Objection
SL	8/7/2000	Email from Andrea Landsberg to Bruce McCarthy re 594 Development Plan	ABBT0109806-39	No Objection
SM	10/3/2000	Email from Bruce McCarthy to Andrea Landsberg re ABT-594/963 Purdue Meeting	ABBT0107081	No Objection
SN	00/00/00	Portfolio Review Meeting, March 7-9, 2001	ABBT0092919-21	No Objection
SO	9/00/2000	Pharmaceuticals Strategy Update	ABBT0155493-512	No Objection
SP	9/00/2000	Pharmaceuticals Strategy Update	ABBT0577835-54	No Objection